Corrigendum to A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma [AnnOncol 2013, 24, 3076-3081] doi: 10.1093/annonc/mdt414

A. M. Evens, K. R. Carson, J. Kolesar, C. Nabhan, I. Helenowski, N. Islam, B. Jovanovic, P. M. Barr, P. F. Caimi, S. A. Gregory, L. I. Gordon

Research output: Contribution to journalComment/debate

Original languageEnglish
Article numbermdu179
Number of pages1
JournalAnnals of Oncology
Issue number7
StatePublished - Jul 2014

Cite this